From concept to clinic: Our focus is to rapidly develop immune modulation therapies for infectious diseases and cancer

Themis has developed a sophisticated vaccine platform and broad pipeline based on the advanced understanding of immune system mechanisms. Initially focused on preventing infectious diseases, the Company has demonstrated the potential of its versatile platform through the rapid progression into Phase 2 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading global VCs, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and manufacturing capabilities to diseases with high market potential both alone and for its partners.